Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Technique Rapidly Detects Needle-in-a-Haystack Plasma Biomarkers for Disease Diagnosis

By LabMedica International staff writers
Posted on 12 May 2023

Blood plasma, routinely collected during medical care and research, has the potential to be an abundant source of protein biomarkers. More...

These markers can serve diagnostic and prognostic roles, measure treatment response, and provide insights into disease biology. However, finding such biomarkers in plasma using proteomics, the most advanced tool currently available, is challenging. This is because 99% of plasma is composed of common proteins like albumin, globulins, and coagulants that essentially hide potential biomarkers. These same proteins are repeatedly identified in a plasma sample, making the detection of the less abundant but interesting proteins difficult. While scientists have attempted to remove these common proteins from plasma samples using antibodies, the process has been found to be costly, time-consuming, and not robust enough for large-scale usage. Now, a team of researchers has developed a new, rapid, and cost-effective method to remove these proteins by repurposing an old biochemical technique from 1948.

Researchers at Boston Children's Hospital (Boston, MA, USA) came upon a technique previously mentioned in literature on protein and peptide studies that could be applied to plasma. During the COVID-19 pandemic, the researchers were tasked with analyzing the proteins in 5,000 plasma samples for a study looking at immune responses in about 1,100 hospitalized COVID-19 patients. This task had to be accomplished at a time when many labs were closed due to the pandemic. In a span of three months, the researchers had to develop a method to analyze ten times the amount of plasma samples than they typically handled daily. The team successfully accomplished this task, and their work contributed to the identification of tissue- and organ-specific biomarkers, which accurately predicted the progression of hospitalized COVID-19 patients.

This new technique employs perchloric acid, a very potent superacid, along with very low temperatures (-20°C) to separate the common proteins within as little as 15 minutes, without harming the remaining proteins. The unwanted proteins coagulate similar to how milk curdles in lemon juice. The samples can then be centrifuged, and the liquid at the top, which contains the required proteins, can be collected. This method is fast enough for large-scale use, depleting the unwanted proteins at a cost of only USD 2.50 per sample, significantly lower than current costs. This technique enables the detection of over 1,500 proteins per sample at a rate of 60 samples per day.

Related Links:
Boston Children's Hospital 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.